二甲双胍对可切除非小细胞肺癌患者远期生存的影响

目的探讨二甲双胍对可切除非小细胞肺癌（NSCLC）合并2型糖尿病患者预后的影响。 方法回顾性分析2011年1月至2015年12月177例可切除的NSCLC合并2型糖尿病患者临床病理资料。 结果全组患者中位生存期和第1、3、5年生存率分别为47.0个月和87.3%、54.7%、22.6%。二甲双胍组中位生存期和第1、3、5年生存率分别为49.0个月和93.7%、67.0%、32.3%，非二甲双胍组中位生存期和第1、3、5年生存率分别为42.0个月和85.7%、53.4%、18.7%。单因素分析发现，二甲双胍、TNM分期、辅助化疗与辅助放疗与预后显著相关（P<0.05）。多因素分析显示，二甲双胍和TNM分期是影响可切除NSCLC合并2型糖尿病患者预后的独立因素（P<0.05）。 结论服用二甲双胍的可切除的NSCLC合并2型糖尿病患者远期生存更好。

Effect of metformin on long-term survival of patients with resectable non-small cell lung cancer

ObjectiveTo investigate the effect of metformin on the prognosis of resectable non-small cell lung cancer (NSCLC) complicated with type 2 diabetes mellitus. MethodsA retrospective review of 177 patients with NSCLC complicated with type 2 diabetes who were resectable between January 2011 and December 2015 was performed. The prognostic impact of different therapy and the clinicopathologic factors were analyzed. ResultsThe overall median survival time and the 1-, 3-, and 5-year overall survival rates were 47.0 months, 87.3%, 54.7% and 22.6%, respectively. The median survival time and 1-, 3- and 5-year survival rates of metformin group were 49.0 months and 93.7%, 67.0%, 32.3%, respectively, while those of non-metformin group were 42.0 months and 85.7%, 53.4%, 18.7%, respectively. Univariate analysis showed that metformin, TNM stage, adjuvant chemotherapy and adjuvant radiotherapy had significant differences in prognosis (P<0.05) . Multivariate analysis showed, metformin and TNM stage were independent factors affecting the prognosis of resectable NSCLC patients with type 2 diabetes mellitus (P<0.05) . ConclusionLong-term survival is better in patients with resectable NSCLC with type 2 diabetes mellitus taking metformin.